Adamis Pharma Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Adamis Pharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Adamis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Adamis Pharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Adamis |
Adamis Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Adamis Pharma on November 20, 2025 and sell it today you would earn a total of 100.00 from holding Adamis Pharma or generate -100.0% return on investment over 90 days. Adamis Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Adamis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adamis Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adamis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adamis Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Adamis Pharma is not yet fully synchronised with the market data | |
| Adamis Pharma has some characteristics of a very speculative penny stock | |
| Adamis Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.76 M. Net Loss for the year was (26.48 M) with loss before overhead, payroll, taxes, and interest of (1.43 M). | |
| Adamis Pharma currently holds about 8.88 M in cash with (25.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. |
Adamis Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adamis Stock often depends not only on the future outlook of the current and potential Adamis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adamis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 149.9 M | |
| Cash And Short Term Investments | 1.1 M |
Adamis Pharma Fundamentals Growth
Adamis Stock prices reflect investors' perceptions of the future prospects and financial health of Adamis Pharma, and Adamis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adamis Stock performance.
| Return On Equity | -7.85 | |||
| Return On Asset | -1.04 | |||
| Operating Margin | (3.74) % | |||
| Current Valuation | 7.28 M | |||
| Shares Outstanding | 9.36 M | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 8.62 X | |||
| Price To Sales | 17.64 X | |||
| Revenue | 4.76 M | |||
| EBITDA | (24.27 M) | |||
| Cash And Equivalents | 8.88 M | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 342.56 K | |||
| Debt To Equity | 0.16 % | |||
| Book Value Per Share | (4.24) X | |||
| Cash Flow From Operations | (25.9 M) | |||
| Earnings Per Share | (10.14) X | |||
| Total Asset | 10.93 M | |||
| Retained Earnings | (304.56 M) | |||
| Current Asset | 4.15 M | |||
| Current Liabilities | 2.75 M | |||
Things to note about Adamis Pharma performance evaluation
Checking the ongoing alerts about Adamis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adamis Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adamis Pharma is not yet fully synchronised with the market data | |
| Adamis Pharma has some characteristics of a very speculative penny stock | |
| Adamis Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.76 M. Net Loss for the year was (26.48 M) with loss before overhead, payroll, taxes, and interest of (1.43 M). | |
| Adamis Pharma currently holds about 8.88 M in cash with (25.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. |
- Analyzing Adamis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adamis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Adamis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adamis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adamis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adamis Pharma's stock. These opinions can provide insight into Adamis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Adamis Stock
If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |